EPAS1 and cancer: Since the identification of a water-bound cavity within the crystal structure of HIF-2α PAS-B domain35,40, artificial small-molecule inhibitors targeting this pocket have been discovered and developed into an FDA-approved anti-cancer drug belzutifan41 (also known as MK-6482 and PT2977), highlighting the regulatory potential of HIF-2α by ligands.